Breadcrumb
  1. Home
  2. 340B Drug Pricing Program
  3. Manufacturer Notices to Covered Entities

Manufacturer Notices to Covered Entities

2023

Novo Nordisk Notice Regarding 340B Price Adjustments for Select Products (PDF - 105 KB)

SpecGx LLC Recalculated 340B ceiling prices for certain products for 3Q20–1Q23 (PDF - 227 KB)

Notice Regarding 340B Price Adjustment for Select Jazz Pharmaceutical Products (PDF - 98 KB)

GSK Notice Regarding Adjustment of 340B Prices for Selected Products 4Q21 (PDF - 138 KB)

Biocon Biologics NDC Change and Replenishment for Insulin Glargine-YFGN (PDF - 79 KB)

Biocon Notice of NDC Change and Replenishment for OGIVRI/FULPHILA (PDF - 226 KB)

Granules Pharmaceuticals Notice of Refunds Q4 2021 to Q2 2023 (PDF - 119 KB)

Noven Recalculated Ceiling Price Notice to Covered Entities (PDF - 176 KB)

Novartis Notice Regarding Locametz and Netspot (PDF - 162 KB)

Eli Lilly Notice Regarding Price Changes (PDF - 113 KB)

Novo Nordisk Notice Regarding Price Adjustments (PDF - 99 KB)

Amgen Notice Regarding Availability of Certain Kanjinti NDCs (PDF - 96 KB)

Novo Nordisk Notice of refunds 1Q-2Q 2023 Ozempic (PDF - 77 KB)

WG Critical Care Notice of Refunds 2Q 2022 (PDF - 537 KB)

Merck Notice of Refunds to Covered Entities 3Q 2020 (PDF - 146 KB)

Johnson & Johnson Notice of Refunds to Covered Entities 3Q2020 (PDF - 156 KB)

Tolmar Notice of Refunds 4Q2017 to 4Q2022 (PDF - 137 KB)

Purdue Notice of 340B Price Changes (PDF - 169 KB)

Meitheal Notice Regarding 340B Refunds (PDF - 195 KB)

GSK Notice of Refunds to Covered Entities Q3 2021 (PDF - 126 KB)

Amgen Notice Regarding Refunds to 340B Covered Entities Q3 2020 – Q4 2020 (PDF - 116 KB)

Vertex Pharma Notice of Refunds to Covered Entities 4Q2022 to Q2 2023 (PDF - 105 KB)

Notice to 340B covered entities regarding ANDEXXA replenishment (PDF - 110 KB)

Amring Refund Notice to 340B Covered Entities (PDF - 162 KB)

VistaPharm Notice Regarding Recalculated 340B Ceiling Prices (PDF - 211 KB)

Eli Lilly and Company Notice of Refunds to Covered Entities 3Q 2020 (PDF - 113 KB)

Novo Nordisk Inc. Notice of Refunds to Covered Entities Q3 2020 (PDF - 110 KB)

Neurocrine Notice Regarding Offer of Refunds to 340B Covered Entities for 3Q2022 – 2Q2023 (PDF - 168 KB)

Amneal Notice Regarding Lioresal Intrathecal Baclofen NDC Change and Replenishment (PDF - 191 KB)

Merck Notice of Refunds to Covered Entities Q2 2020 (PDF - 84 KB)

SK Life Sciences Notice of Refunds to Covered Entities Q3 2021 through Q2 2022 (PDF - 134 KB)

Merck Notice of Refunds to Covered Entities Q1 2020 (PDF - 170 KB)

Amgen Notice of Refunds to Covered Entities Q1-Q2 2020 (PDF - 118 KB)

GSK Notice of Refunds to Covered Entities Q2 2021 (PDF - 126 KB)

Johnson and Johnson Notice Regarding Refunds to  340B Covered Entities (PDF - 122 KB)

Chartwell Rx LLC Notice of Refunds to Covered Entities Q4 2022 (PDF - 112 KB)

Lifestar Pharma Notice of Refunds to Covered Entities Q4 2022 (PDF - 132 KB)

Astellas Notice Regarding Cresemba NDC Change and Replenishment (PDF - 109 KB)

Daiichi Sankyo, Inc Notice to Regarding Refunds for Certain Products (PDF - 111 KB)

Dermavant Sciences Inc. Notice of Refunds to Covered Entities for 2Q 2022 – 1Q 2023 (PDF - 167 KB)

Viatris Notice Regarding NDC Changes (PDF - 91 KB)

Amneal Notice of Refunds to Covered Entities 3Q 2019-3Q 2022 (PDF - 631 KB)

Zydus Pharmaceuticals Notice of Refunds to Covered Entities 1Q 2022-3Q 2022 (PDF - 186 KB)

GSK Notice Regarding Adjustment of 340B Price (PDF - 137 KB)

Astellas Notice Regarding Cresemba NDC Change (PDF - 82 KB)

J&J Notice Regarding Refunds to Covered Entities (PDF - 176 KB)

Alcon Laboratories, Inc. Notice Regarding Refunds to 340B Covered Entities (PDF - 138 KB)

Accessibility

If you use assistive technology, you may not be able to fully access information in these files. For assistance, please email 340B-Communication@hrsa.gov.

Date Last Reviewed: